SCHEMBL6325733

SCHEMBL6325733

O=C(Nc1ccc(C(=O)c2ccc(-n3cncn3)cc2)cc1)Nc1nnc(-c2cc(Cl)cc(Cl)c2O)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 12/20 0.46
HTT P42858 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
KDM4E B2RXH2 3/20 0.42
MCL1 Q07820 3/20 0.42
RAB9A P51151 3/20 0.42
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 3/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
WRN Q14191 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
DNMT1 P26358 1/20 0.41
DUSP3 P51452 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
S1PR1 P21453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326921 0.95 BLM (0.49) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6444272 0.89 RXFP1 (0.48) BLMKDM4ERAB9ARXFP1POLB
SCHEMBL6329492 0.85 BLM (0.45) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6322384 0.85 BLM (0.43) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6326664 0.85 BLM (0.46) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6323159 0.84 BLM (0.57) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6323345 0.83 RAB9A (0.50) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6329453 0.82 BLM (0.52) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6325012 0.82 RAB9A (0.55) BLMHTTSMN1; SMN2KDM4EMCL1
SCHEMBL6321561 0.80 BLM (0.54) BLMHTTSMN1; SMN2KDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US claimed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 BLM 2929/4885HTT 2797/4885SMN1; SMN2 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.